ASCO 2019 Report — Breast Cancer

Highlights of the latest treatments

At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Editor-in-Chief William J. Gradishar, MD, reviews the key presentations on new breast cancer therapies. All meeting abstracts can be viewed in the (ASCO meeting library).

Ribociclib for ER-Positive/HER2-Negative Metastatic Breast Cancer

CDK 4/6 agents have been the main story in hormone-sensitive metastatic breast cancer since randomized clinical trials have consistently shown that progression-free survival (PFS) is enhanced with CDK 4/6 inhibitors plu…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)